---
title: "LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293470551.md"
description: "LB Pharmaceuticals announced an acceleration in the timeline for its Phase 3 NOVA-2 trial data on LB-102 for schizophrenia, now expected in H1 2027. A pre-NDA meeting with the FDA is targeted for H2 2027. The trial plans to enroll approximately 460 patients across 25 U.S. sites."
datetime: "2026-07-22T12:04:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293470551.md)
  - [en](https://longbridge.com/en/news/293470551.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293470551.md)
generator: "portal-rs"
---

# LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline

-   LB Pharmaceuticals posted a press release accelerating expected topline timing for Phase 3 NOVA-2 data for LB-102 in schizophrenia to H1 2027. \* Pre-NDA meeting with the FDA now targeted for H2 2027. \* NOVA-2 plans to enroll about 460 patients across 25 U.S. sites. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220800PRIMZONEFULLFEED9766044) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)

## Related News & Research

- [LBRX: LB-102 shows rapid, robust efficacy and safety in late-stage trials, targeting broad neuropsychiatric markets](https://longbridge.com/en/news/295535099.md)
- [LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained](https://longbridge.com/en/news/293644868.md)
- [Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study](https://longbridge.com/en/news/296635926.md)
- [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md)
- [Clearfield targets $18 billion hyperscaler fiber market with NOVA high-density panel push](https://longbridge.com/en/news/296660707.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**